The U.S. FDA has agreed to review Moderna’s mRNA flu vaccine after initially declining, as next-generation RSV vaccines advance to address evolving viral strains. RSV continues to pose risks for older ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE (COVID-19 Vaccine, mRNA), which targets the LP.8.1 variant of SARS-CoV-2. The data ...